LabCorp, Epic Expand Tech for Asian Oncology Trials
Epic Sciences announced an agreement with LabCorp to provide circulating tumor cell (CTC) technology and support oncology clinical trials in Asia through Covance Drug Development.
Epic Sciences announced an agreement with LabCorp to provide circulating tumor cell (CTC) technology and support oncology clinical trials in Asia through Covance Drug Development. Covance will process patient samples in Singapore, and then send samples to Epic's clinical laboratory in San Diego. This agreement expands on a previous contract announced last year between Epic and LabCorp for European clinical trials.
Epic's blood sample-based CTC technology can incorporate CTC enumeration, quantitative protein biomarker analysis and single-cell genomic analysis by next generation sequencing (NGS) or fluorescent in situ hybridization (FISH) to give a comprehensive picture of a patient's cancer. Its lab in San Diego was recently licensed under the Clinical Laboratory Improvement Amendments (CLIA) of 1988, for downstream detection and molecular characterization of CTCs.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- How the NIMBLE Study Supported Adherence With Quarterly Dosing of Cemdisiran
September 18th 2025
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025